- Enhanced radial introducer sheaths feature superior sheath-to-dilator transition and extended hydrophilic coating for smooth radial access
- 17 models and three kit configurations designed to meet the needs of a variety of radial access techniques
- Radial access remains one of the fastest-growing cardiac cath lab practice trends in the U.S.
MINNEAPOLIS, Jan. 25, 2016 -- Vascular Solutions, Inc. (Nasdaq:VASC) today announced the launch in the United States of its enhanced line of VSI Radial introducer sheaths for use in the introduction of guidewires and catheters into veins and arteries. The VSI Radial introducer sheaths are specifically designed for patients undergoing transradial catheterization procedures, one of the fastest-growing practices in the field of interventional cardiology in the U.S.
The new versions of the VSI Radial introducer sheaths enhance the original versions that were launched in early 2015. The new versions feature a superior sheath-to-dilator transition and an extended hydrophilic coating that includes both the sheath and the dilator. In addition, an angled tip wire has been added to the options.
“Vascular Solutions is committed to providing a complete range of specialized devices for radial artery catheterization procedures, and therefore we are excited by the availability of our new introducer sheaths,” said Howard Root, CEO of Vascular Solutions. “Radial access procedures represented fewer than 2% of all cardiac catheterization procedures in the U.S. just seven years ago. Today, we believe radial access is used in approximately 25% of cath lab procedures. Yet, we expect this percentage to continue to grow over the next several years, and Vascular Solutions is well-positioned to contribute to and benefit from this major trend in U.S. interventional practice.”
Vascular Solutions now offers 17 models of the VSI Radial introducer sheaths. The sheaths are available in 4F, 5F, and 6F diameters and in 7cm, 11cm, and 24cm lengths. Three kit configurations are available to accommodate a variety of radial access techniques: standard kits designed for the single-wall micro-puncture technique, access kits designed for the double-wall micro-puncture technique, and 0.035” kits designed for converting a 4F or 5F diagnostic procedure into a 6F intervention.
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company’s product line consists of more than 90 products and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network.
The information in this press release contains forward-looking statements about Vascular Solutions that involve risks and uncertainties. Vascular Solutions’ actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in the company Annual Report on Form 10-K for the year ended December 31, 2015 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of the company’s new products, defense of criminal litigation, exposure to potential shareholder litigation, exposure to intellectual property claims and litigation, significant variability in quarterly results, exposure to possible product liability claims, doing business in international markets, the development of new products by others, the company’s reliance on the development of new products and services, constraints or interruptions in production from key suppliers, breaches or other failures of information technology and communications systems, the availability of third party reimbursement, and actions by government regulatory agencies.
For further information, connect to www.vasc.com.
Contact: Vascular Solutions, Inc. Phil Nalbone, VP-Corp. Dev. [email protected] (763) 656-4371


Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Robinhood Expands Sports Event Contracts With Player Performance Wagers 



